Olanzapine plus metoclopramide to prevent opioid-related nausea and vomiting

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3, randomized (1:1) trial enrolls adults with locally advanced or metastatic cancer who are initiating potent opioid therapy and have moderate to severe cancer pain. Participants receive either olanzapine 2.5 mg nightly plus metoclopramide 10 mg three times daily for 7 days or no prophylactic antiemetic; both groups may get treatment if OINV appears. Investigators record incidence of opioid-induced nausea and vomiting, time to first episode, duration, opioid use changes, and adverse events during follow-up. The trial is conducted at a single center (Affiliated Hospital of Qinghai University) in Xining, Qinghai.

Why it matters

Who can join: the full rules

Inclusion criteria

1. Patients with malignant tumors diagnosed by pathology or histology;
2. Patients diagnosed with locally advanced or advanced stages by imaging;
3. Age ≥ 18 years old;
4. The eastern cooperative oncology group (ECOG) performance status of 0-3;
5. The expected survival period shall be no less than 4 weeks;
6. Moderate or severe cancer pain with a Numerical Rating Scale (NRS) score of ≥ 4 points;
7. Be able to take oral medication;
8. Initial treatment with potent opioid painkillers (such as morphine, oxycodone, fentanyl, etc.);
9. No systemic chemotherapy or radiotherapy was received within one month prior to selection, and no drugs that may induce nausea and vomiting were used.
10. There were no gastrointestinal discomforts such as nausea or vomiting at the time of selection, and no intestinal obstruction.
11. Possess normal comprehension and communication skills, be capable of completing research evaluations and following research procedures.

Exclusion criteria

1. Diabetic patients with a clear diagnosis and poorly controlled blood sugar levels;
2. There are symptoms of nausea or vomiting;
3. Symptomatic intracranial diseases, such as brain metastases or leptomeningeal metastasis;
4. Received chemotherapy drug treatment within one week before the trial medication or during the trial period;
5. Receive radiotherapy for the head, abdomen or pelvic cavity within one week before the trial or during the trial;
6. New drugs with emetic or antiemetic effects have been used within 48 hours before the start of the trial;
7. Patients with severe electrolyte imbalance, abnormal kidney or liver function;
8. Patients with gastrointestinal bleeding;
9. Pregnant or lactating women;
10. Patients diagnosed with breast cancer;
11. Those whose electrocardiogram examination indicates heart disease or prolonged QTc interval;
12. There is a history of allergy or contraindications to olanzapine or metoclopramide.

Where it's running

• Qinghai University Affiliated Hospital
  Xining, Qinghai, China Recruiting

Study contacts

• Study coordinator: Jiuda Zhao, Doctor
• Email: jiudazhao@126.com
• Phone: 09716230893

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HR20013 for preventing nausea and vomiting in cancer patients receiving chemotherapy

  This real-world study tests whether HR20013 helps prevent nausea and vomiting in adults with cancer who are getting chemotherapy.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07874308

• LY3537021 for preventing chemo-related nausea and vomiting in adults

  This trial will test whether adding LY3537021 to standard anti-nausea care helps prevent nausea and vomiting in adults starting AC or high-dose cisplatin chemotherapy.

  Recruiting at 58 sites Phase 2 Eli Lilly and Company · Greenbrae, California and 66 other locations · NCT07169851

• Using periorbital massage to reduce nausea and vomiting after gallbladder surgery

  This study tests if a gentle massage around the eyes can help reduce nausea and vomiting in adults after gallbladder surgery.

  Recruiting Atlas University · Gaziantep · NCT06954935

• Treatment of marginal ulcers using low-thermal argon plasma

  This study is testing if a new low-thermal argon plasma treatment can help heal stubborn ulcers that some people get after weight loss surgery, to see if it works better than the usual medicine.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT06543316

• Using Enterra Therapy to Treat Chronic Nausea and Vomiting

  This study is testing whether the Enterra Therapy System can help people with chronic nausea and vomiting feel better and improve their quality of life.

  Recruiting at 22 sites Enterra Medical, Inc. · Scottsdale, Arizona and 21 other locations · NCT06464926

• Using Fosaprepitant to Treat Nausea and Vomiting

  This study is testing if a new medication called fosaprepitant can help people with nausea and vomiting feel better compared to the usual treatment they receive.

  Recruiting Phase 2/3 Montefiore Medical Center · The Bronx, New York · NCT06382012

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.